Histrelin

Histrelin (pGlu-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt; CAS 76712-82-8, free base; molecular formula C66H86N18O12; molecular weight 1323.53) is a synthetic nonapeptide analog of the hypothalamic decapeptide gonadotropin-releasing hormone (GnRH, also designated luteinizing hormone-releasing hormone, LHRH) distinguished from other members of the clinical GnRH agonist class by exceptionally high receptor binding affinity and by a unique formulation as a once-yearly subcutaneous hydrogel polymer implant [1, 2]. The compound incorporates two structural modifications to native GnRH that collectively confer superagonist potency and metabolic stability: replacement of glycine at position 6 with D-histidine bearing an N-benzyl substituent on the imidazole ring, which eliminates the principal endopeptidase cleavage site and introduces a bulky aromatic moiety favorable to hydrophobic interaction with the GnRH receptor transmembrane domain; and replacement of the C-terminal glycinamide (position 10) with an ethylamide, which further resists carboxypeptidase degradation [3, 4]. The resulting peptide binds the type I GnRH receptor with affinity approximately 100- to 200-fold greater than native GnRH and produces the characteristic biphasic pharmacological response common to all GnRH superagonists [5, 6]. Acute administration stimulates pituitary gonadotroph secretion of luteinizing hormone and follicle-stimulating hormone, producing transient elevations in gonadal steroid output (the "flare" phase, lasting 7 to 14 days). Chronic continuous administration produces homologous desensitization of the GnRH receptor through receptor internalization, uncoupling from Gq/11-phospholipase C signaling, and transcriptional downregulation of GnRH receptor expression, resulting in profound and sustained suppression of gonadotropin secretion and a hypogonadal state equivalent to surgical castration in both sexes [5, 6, 7]. Histrelin was initially developed at Ortho Pharmaceutical Corporation (a Johnson and Johnson subsidiary) in the early 1980s and studied in daily subcutaneous injection formulations for central precocious puberty, prostate cancer, and endometriosis [8, 9]. The compound was subsequently reformulated by Roberts Laboratories (later acquired by Shire Pharmaceuticals, then Endo Pharmaceuticals) into a diffusion-controlled hydrogel polymer reservoir subcutaneous implant delivering approximately 65 micrograms of histrelin acetate per day over 12 months [10, 11]. This implant technology produced two FDA-approved products: Vantas (50 mg histrelin acetate implant for palliative treatment of advanced prostate cancer, approved October 2004) and Supprelin LA (50 mg histrelin acetate implant for central precocious puberty, approved May 2007) [12, 13]. Vantas was discontinued in 2020 owing to manufacturing quality issues at the production facility; Supprelin LA remains commercially available. Pharmacokinetics of the implant formulation are characterized by sustained zero-order drug release producing median steady-state serum histrelin concentrations of approximately 0.2 to 0.4 ng/mL, with a terminal elimination half-life of the released peptide of approximately 4 hours, 92 percent subcutaneous bioavailability, and approximately 70 percent plasma protein binding [10, 14]. Metabolism is hepatic through peptidase-mediated degradation. The adverse-event profile is dominated by the pharmacological consequences of gonadal steroid suppression: hot flashes, reduced libido, erectile dysfunction or amenorrhea, and long-term bone mineral density reduction. Implant site reactions (bruising, pain, erythema) occur in approximately 50 percent of recipients. The initial flare phase carries specific risk in metastatic prostate cancer, which is mitigated by co-administration of an antiandrogen during the first 2 to 4 weeks of therapy. Postmarketing surveillance has identified rare but serious adverse events including pseudotumor cerebri, seizures, psychiatric symptoms (emotional lability, depression, suicidal ideation), and severe cutaneous adverse reactions. This monograph reviews the chemistry and synthesis, the biphasic GnRH receptor pharmacology, the comprehensive human pharmacokinetic record, the clinical evidence base across prostate cancer, central precocious puberty, endometriosis, and gender-affirming therapy indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five GnRH agonist candidates against histrelin on five competency standards.